AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33515055 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective water vapor thermal energy therapy (WAVE)
Number of subjects: 2
Study 33515055 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL)
Number of subjects: 2
Study 33515429 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of Src Family Kinases (SFKs)
Number of subjects: 0
Study 33515429 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of Inducible Nitric Oxide Synthase (iNOS)
Number of subjects: 0
Study 33515429 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of NADPH Oxidase 2 (NOX2)
Number of subjects: 0
Study 33516161 — intervention group
Group type: EXPERIMENTAL
Intervention: GLE/PIB
Number of subjects: 109
Study 33516189 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of over-eating
Number of subjects: 555
Study 33516189 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of a regular schedule
Number of subjects: 555
Study 33516189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise almost every day
Number of subjects: 555
Study 33516189 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular schedule almost every day
Number of subjects: 555
Study 33516189 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of over-eating half of the time
Number of subjects: 555
Study 33516200 — intervention group
Group type: EXPERIMENTAL
Intervention: CADMaHL model development with input from stakeholders
Number of subjects: 0
Study 33516200 — intervention group
Group type: EXPERIMENTAL
Intervention: CADMaHL model
Number of subjects: 0
Study 33516211 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-GINET21 questionnaire
Number of subjects: 199
Study 33516215 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest triglyceride quartile
Number of subjects: 15773
Study 33516215 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest TG:HDL quartile
Number of subjects: 15773
Study 33516215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest HDL cholesterol quartile
Number of subjects: 15773
Study 33516215 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest vs lowest triglyceride quartile (males)
Number of subjects: 15773
Study 33516215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest vs highest HDL cholesterol quartile (females)
Number of subjects: 15773
Study 33516247 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome enrichment NGS from fecal samples
Number of subjects: 14
Study 33516248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of biological markers
Number of subjects: 116
Study 33516560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day for 8 weeks
Number of subjects: 143
Study 33516721 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib interruption (≥ 2 interruptions)
Number of subjects: 408
Study 33516721 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib interruption after ≥ 6 months of treatment
Number of subjects: 408
Study 33516721 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib interruption with dose reduction
Number of subjects: 408
Study 33516721 — intervention group
Group type: EXPERIMENTAL
Intervention: Time off therapy of ≥ 8%
Number of subjects: 408
Study 33517043 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (conventional fractionation and hypofractionation); dose range: 43.4 to 71.0 Gy (median dose: 48.6 Gy); boost radiation therapy administered to 49 patients.
Number of subjects: 314
Study 33517043 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing EQD2 per Gy (odds ratio [OR]: 1.58, 95% CI: 1.26-1.98; p < 0.001)
Number of subjects: 314
Study 33517043 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status (OR: 25.48, 95% CI: 1.56-415.65; p = 0.023)
Number of subjects: 314
Study 33517043 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic breast reconstruction (OR: 9.28, 95% CI: 1.84-46.70; p = 0.007)
Number of subjects: 314
Study 33517185 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib discontinuation
Number of subjects: 31
Study 33517185 — intervention group
Group type: EXPERIMENTAL
Intervention: MR4.5
Number of subjects: 31
Study 33517185 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NK cell levels
Number of subjects: 31
Study 33517477 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) discontinuation
Number of subjects: 260
Study 33517701 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment on hospital admission (21.7%)
Number of subjects: 1275
Study 33517701 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of prior statin treatment
Number of subjects: 1275
Study 33517701 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of statins during the first days after ICH
Number of subjects: 1275
Study 33517701 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins initiated at hospital discharge
Number of subjects: 1275
Study 33517769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years)
Number of subjects: 0
Study 33518355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 375-750 mg (single-dose and multiple-dose)
Number of subjects: 118
Study 33518355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 118
Study 33518442 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Beliefs Scale (HLB)
Number of subjects: 0
Study 33518523 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (lactate, hs-cTnT, NT-proBNP, D-dimer, procalcitonin) measured on arrival.
Number of subjects: 450
Study 33519187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 40
Study 33519187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 40
Study 33519339 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) transfusion (300 ml, 200-400 ml/treatment dose) at least once, up to 5 sessions, along with best standard of care.
Number of subjects: 40
Study 33519339 — intervention group
Group type: COMPARATOR
Intervention: Best standard of care only (control group).
Number of subjects: 40
Study 33519425 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention (3 units of 45 min) of aerobic exercise (AE)
Number of subjects: 183
Study 33519425 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 183
Study 33519487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0
Study 33519487 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33519659 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective dual-task turning measures during assessments with inertial sensors
Number of subjects: 0
Study 33519659 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment prior to rehabilitation
Number of subjects: 0
Study 33519659 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-rehabilitation assessment after completion of rehabilitation
Number of subjects: 0
Study 33519698 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33520317 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release pirfenidone (PR-PFD) 1,200 mg/day
Number of subjects: 88
Study 33520317 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release pirfenidone (PR-PFD) 600 mg/day
Number of subjects: 88
Study 33520317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 33520402 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33520670 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended transdiagnostic group CBT
Number of subjects: 30
Study 33521019 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen Tripeptide
Number of subjects: 0
Study 33521019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33521037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented High-Fiber Rye Diet
Number of subjects: 0
Study 33521522 — intervention group
Group type: EXPERIMENTAL
Intervention: healthy plant-based diet index (hPDI)
Number of subjects: 4680
Study 33521522 — intervention group
Group type: EXPERIMENTAL
Intervention: unhealthy plant-based diet index (uPDI)
Number of subjects: 4680
Study 33521534 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical prescriptions for fresh vegetables (21 servings/week for 10 weeks)
Number of subjects: 159
Study 33521537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Risk Score (DRS)
Number of subjects: 126
Study 33521537 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI)-2015
Number of subjects: 126
Study 33521539 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 158
Study 33521539 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum perfluorooctanesulfonic acid (PFOS) concentrations
Number of subjects: 158
Study 33521539 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 30-39 years
Number of subjects: 158
Study 33521539 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PFASs
Number of subjects: 158
Study 33521643 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal IV fluid regimen
Number of subjects: 161
Study 33521643 — intervention group
Group type: COMPARATOR
Intervention: Restrictive IV fluid regimen
Number of subjects: 161
Study 33521873 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18 Flurpiridaz PET myocardial perfusion imaging (MPI)
Number of subjects: 0
Study 33522296 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training or support (specific details not provided)
Number of subjects: 0
Study 33522296 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33522900 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva, plasma, and cerebrospinal fluid (CSF) samples from NeuP patients
Number of subjects: 13
Study 33522900 — intervention group
Group type: COMPARATOR
Intervention: Saliva, plasma, and cerebrospinal fluid (CSF) samples from healthy controls
Number of subjects: 13
Study 33522900 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteins
Number of subjects: 13
Study 33522900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of YKL-40 and MIP-1α in saliva
Number of subjects: 13
Study 33522962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation system
Number of subjects: 40
Study 33522962 — intervention group
Group type: COMPARATOR
Intervention: Usual care (in-person rehabilitation)
Number of subjects: 40
Study 33522978 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app for tracking hypertension
Number of subjects: 200
Study 33522978 — intervention group
Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 200
Study 33522978 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial My App platform
Number of subjects: 200
Study 33523330 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME Program
Number of subjects: 0
Study 33523330 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 0
Study 33523334 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836826 in combination with gemcitabine and oxaliplatin
Number of subjects: 0
Study 33523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic features from contrast-enhanced CT (ceCT)
Number of subjects: 39
Study 33523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic features from non-contrast-enhanced CT (non-ceCT)
Number of subjects: 39
Study 33523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic features from ceCT
Number of subjects: 39
Study 33523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ceCT features
Number of subjects: 39
Study 33523367 — intervention group
Group type: EXPERIMENTAL
Intervention: ceCT features
Number of subjects: 39
Study 33523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CT 'necrosis'
Number of subjects: 39
Study 33523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CT 'arterial vascular invasion'
Number of subjects: 39
Study 33523367 — intervention group
Group type: COMPARATOR
Intervention: Conventional-imaged-based-parameters
Number of subjects: 39
Study 33523609 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer convalescent plasma
Number of subjects: 3082
Study 33523609 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-titer convalescent plasma
Number of subjects: 3082
Study 33523609 — intervention group
Group type: COMPARATOR
Intervention: Low-titer convalescent plasma
Number of subjects: 3082
Study 33523609 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer convalescent plasma (non-mechanical ventilation)
Number of subjects: 3082
Study 33523609 — intervention group
Group type: COMPARATOR
Intervention: Low-titer convalescent plasma (non-mechanical ventilation)
Number of subjects: 3082
Study 33523760 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33524144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending growth profile (n=82)
Number of subjects: 332
Study 33524144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate growth profile (n=351)
Number of subjects: 332
Study 33524144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending growth profile
Number of subjects: 332
Study 33524144 — intervention group
Group type: COMPARATOR
Intervention: Meeting intervention goals and exclusive breastfeeding for 3 months or more
Number of subjects: 332
Study 33524306 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with chronic bronchitis
Number of subjects: 120
Study 33524306 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 120
Study 33524308 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine-sparing treatment
Number of subjects: 0
Study 33524316 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernourished SEEM participants (n=52)
Number of subjects: 416
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: EED transcriptome
Number of subjects: 416
Study 33524399 — intervention group
Group type: COMPARATOR
Intervention: EED vs. Celiac Disease
Number of subjects: 416
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: EED epigenetic profile
Number of subjects: 416
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal coexpression modules
Number of subjects: 416
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 416
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune response genes
Number of subjects: 416
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced circulating IGF-1
Number of subjects: 416
Study 33524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin and gene signature for lymphocyte activation and dysregulated lipid metabolism
Number of subjects: 416
Study 33524462 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QTc on smartwatch single-lead electrocardiograms (SW-ECGs)
Number of subjects: 85
Study 33524462 — intervention group
Group type: COMPARATOR
Intervention: Manual QTc measurement on 12-lead ECG
Number of subjects: 85
Study 33524462 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AI-QTc and manual QTc
Number of subjects: 85
Study 33524601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, day 1) and Anlotinib (12 mg, day 1-14) every 3 weeks
Number of subjects: 22
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford-12 score
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: HOOS components
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: FJS
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID for Oxford-12
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID for HOOS symptoms
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID for HOOS pain
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID for HOOS function
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID for HOOS sport
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID for HOOS quality of life
Number of subjects: 123
Study 33524632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient improvement ratings
Number of subjects: 123
Study 33524990 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b1 vaccine, one intramuscular dose
Number of subjects: 0
Study 33524990 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine, one intramuscular dose
Number of subjects: 0
Study 33526031 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly challenging and progressive balance training for 10 weeks
Number of subjects: 12
Study 33526148 — intervention group
Group type: EXPERIMENTAL
Intervention: Post stroke intervention program
Number of subjects: 470
Study 33526148 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 470
Study 33526303 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 500
Study 33526329 — intervention group
Group type: COMPARATOR
Intervention: RAMPART
Number of subjects: 3024
Study 33526329 — intervention group
Group type: COMPARATOR
Intervention: PROSPER
Number of subjects: 3024
Study 33526329 — intervention group
Group type: COMPARATOR
Intervention: CheckMate-914
Number of subjects: 3024
Study 33526329 — intervention group
Group type: COMPARATOR
Intervention: Keynote-564
Number of subjects: 3024
Study 33526329 — intervention group
Group type: COMPARATOR
Intervention: IMMotion-010
Number of subjects: 3024
Study 33526480 — intervention group
Group type: EXPERIMENTAL
Intervention: Apollo Onyx delivery microcatheter
Number of subjects: 112
Study 33526606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in younger adolescents (13-15 years)
Number of subjects: 242
Study 33526606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in older adolescents (16-19 years)
Number of subjects: 242
Study 33526820 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture features in early-stage PD patients
Number of subjects: 108
Study 33526820 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture features in late-stage PD patients
Number of subjects: 108
Study 33526820 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study 33526918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease (cGVHD) evaluation
Number of subjects: 275
Study 33526918 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from transplant to cGVHD evaluation
Number of subjects: 275
Study 33526918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior lines of systemic immunosuppressive therapy for cGVHD
Number of subjects: 275
Study 33526918 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 complement level
Number of subjects: 275
Study 33526918 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 275
Study 33527307 — intervention group
Group type: EXPERIMENTAL
Intervention: iCVMapper (CNN for ICV segmentation)
Number of subjects: 528
Study 33527307 — intervention group
Group type: EXPERIMENTAL
Intervention: VentMapper (CNN for ventricular segmentation)
Number of subjects: 528
Study 33527307 — intervention group
Group type: EXPERIMENTAL
Intervention: iCVMapper and VentMapper with CRF post-processing
Number of subjects: 528
Study 33527307 — intervention group
Group type: EXPERIMENTAL
Intervention: iCVMapper and VentMapper
Number of subjects: 528
Study 33527351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian dose regimen assessment method (DRtox)
Number of subjects: 0
Study 33527447 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal (P) and Buccal (G) tissues
Number of subjects: 6
Study 33527447 — intervention group
Group type: EXPERIMENTAL
Intervention: G and P tissues
Number of subjects: 6
Study 33527447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblasts from all tissues
Number of subjects: 6
Study 33527684 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for infrainguinal PAD in CKD patients
Number of subjects: 3699
Study 33527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucite reinforced veneer material
Number of subjects: 0
Study 33527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorapatite glass-ceramic veneer material
Number of subjects: 0
Study 33527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-TZP core zirconia ceramic
Number of subjects: 0
Study 33527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal dimension measurements of flexure bars and FDPs
Number of subjects: 0
Study 33527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical failure analysis of FDP replicates
Number of subjects: 0
Study 33528118 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant subunit herpes zoster vaccine (RZV); 2 doses given 2-6 months apart.
Number of subjects: 23
Study 33528286 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent selinexor
Number of subjects: 0
Study 33528371 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-supported Family Strengthening Intervention for Early Childhood Development (FSI-ECD)
Number of subjects: 100
Study 33528371 — intervention group
Group type: COMPARATOR
Intervention: Standard maternal and child health services
Number of subjects: 100
Study 33528377 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help program with personal guidance and automated email reminders
Number of subjects: 240
Study 33528377 — intervention group
Group type: COMPARATOR
Intervention: Web-based self-help program without personal guidance and automated email reminders
Number of subjects: 240
Study 33528378 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing intervention alone
Number of subjects: 450
Study 33528378 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing combined with an mHealth intervention
Number of subjects: 450
Study 33528378 — intervention group
Group type: COMPARATOR
Intervention: HIV testing standard of care
Number of subjects: 450